-
Mashup Score: 0The VJSessions | VJHemOnc - 7 month(s) ago
Roundtable discussions with leading experts in hematological oncology
Source: www.vjhemonc.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Updates on the use of CAR-T therapy in MCL - 8 month(s) ago
Tycel Phillips, MD, City of Hope, Duarte, CA, shares some insights into the use of CAR-T therapy in mantle cell lymphoma (MCL), highlighting the use of brexucabtagene autoleucel (brexu-cel) as a mainstay treatment in recent years. Dr Phillips comments on the rates of immune effector cell-associated neurotoxicity syndrome (ICANS) observed with the use of this agent, as well as relapse rates. Dr Phillips also talks on lisocabtagene maraleucel (liso-cel), which has not yet been investigated in patients with MCL, but has demonstrated a similar efficacy to brexu-cel with a significantly reduced incidence of ICANS. This interview took place at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023) held in Houston, TX. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Source: www.vjhemonc.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
We caught up with Tycel Phillips (@LymphClinician; @cityofhope), who shared some updates on CAR-T therapy in MCL, highlighting the use of brexu-cel as a mainstay treatment: 🎥 https://t.co/V8S71ArUdg #SOHO23 #LymSM #HemOnc #ImmunoOnc #CARTcell
-
-
Mashup Score: 0MATISSE: nivolumab in cutaneous squamous cell carcinoma - 8 month(s) ago
Charlotte Zuur, Leiden University Medical Centre, Leiden, The Netherlands, outlines the primary objectives and results of the Phase II MATISSE study (NCT02760498) of nivolumab and nivolumab plus ipilimumab (two monoclonal antibodies targeting PD1 and CTLA-4 respectively) in extensive cutaneous squamous cell carcinoma (SCC). The randomised trial enrolled 40 patients with an indication for curative surgery with or without radiotherapy; the study aimed to improve patients’ clinical prospects through immunotherapy and de-escalate surgery and radiotherapy. Dr Zuur shared the promising results of the immunotherapy, stating 90% of patients who refused surgery displayed disease-free survival of 1 year. This interview took place during the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting in Chicago, IL. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved
Source: www.vjoncology.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
🎥Dr Charlotte Zuur (@LUMC_Leiden) discusses promising results from the Phase II MATISSE study using nivolumab and nivolumab plus ipilimumab in extensive cutaneous squamous cell carcinoma: ➡️https://t.co/RI7WRXGEL8⬅️ #ASCO23 #ImmunoOnc #SkcSM #CTSM #TrialUpdate
-
-
Mashup Score: 0
Emrullah Yilmaz, MD, PhD, Cleveland Clinic, Cleveland, OH, describes the rationale behind the addition of BCA101, a bifunctional EGFR/TGFβ inhibitor, with pembrolizumab, a PD-1 antibody, for patients with recurrent, metastatic head and neck squamous cell carcinoma (HNSCC) in a dose expansion trial (NCT04429542). EGFR is an established target, where existing therapies such as cetuximab target EGFR in head and neck cancer. Inhibition of TGFβ additionally has immunomodulatory effects. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Source: www.vjoncology.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
🎥@YilmazMDPhD of @ClevelandClinic discusses combining BCA101 and pembrolizumab for recurrent HNSCC. A promising approach targeting EGFR and TGFβ: ➡️https://t.co/AQjf89AyVB⬅️ #ASCO23 #hncSM #ImmunoOnc
-
-
Mashup Score: 0The future of bispecific antibodies in the treatment and management of R/R follicular lymphoma - 8 month(s) ago
In this video, Graham Collins, MA, MBBS, MRCP, FRCPath, DPhil, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, discusses the value of bispecific antibodies in the treatment of relapsed/refractory (R/R) follicular lymphoma (FL), highlighting agents including mosunetuzumab, epcoritamab and odronextamab. Dr Collins then goes on to comment on the importance of exploring combination approaches with these agents, highlighting the promise of combining bispecifics with lenalidomide. This interview took place at the 17th International Conference on Malignant Lymphoma (ICML), held in Lugano, Switzerland. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Source: www.vjhemonc.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Bispecific antibodies are a valuable treatment option being explored for patients with various subtypes of NHL, including follicular lymphoma. Find out more in our interview w/ @graham74GC: 👉 https://t.co/eFBNd5M9nV #BloodCancerAwarenessMonth #LymSM #HemOnc #ImmunoOnc https://t.co/QW2f83loiN
-
-
Mashup Score: 1Interplay of Immunosuppression and Immunotherapy Among Patients With Cancer and COVID-19 - 8 month(s) ago
This cohort study examines the association between baseline immunosuppression and/or immunotherapy-based therapies with COVID-19 severity and cytokine storm in patients with cancer.
Source: jamanetwork.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Interplay of Immunosuppression and Immunotherapy Among Patients With Cancer and COVID-19 [Nov 3, 2022] @ZiadBakouny et al. @DrChoueiri @TMWiseDraper @COVID19nCCC @JAMAOnc https://t.co/hfCkOciRbV #COVID19nCancer #CCC19 #IDonc #ImmunoOnc #NCT04354701 https://t.co/oi6b5A1Yl0
-
-
Mashup Score: 0MAIN-CAV: maintenance cabozantinib and avelumab in urothelial cancer - 8 month(s) ago
Shilpa Gupta, MD, Cleveland Clinic, Cleveland, OH, talks on the trial design of the Phase III MAIN-CAV trial (NCT05092958) of maintenance cabozantinib and avelumab in patients with metastatic urothelial cancer. Based on the JAVELIN Bladder 100 trial (NCT02603432), maintenance avelumab is considered the standard of care in this setting, but responses remain poor in patients with certain metastases. The MAIN-CAV will assess the addition of cabozantinib in patients pre-treated with platinum-based chemotherapy, and overall survival will be the primary objective. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Source: www.vjoncology.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
🎥@shilpaonc (@ClevelndClinic) discusses the Phase III MAIN-CAV trial, aiming to improve outcomes for patients w/ metastatic UC via maintenance cabozantinib and avelumab: ➡️https://t.co/qMCOgJ49Dg⬅️ #ASCO23 #ImmunoOnc #CTSM #UroOnc #UroSoMe #BlcSM
-
-
Mashup Score: 0Vaccination in Multiple Myeloma: Review of Current Literature - 8 month(s) ago
Multiple myeloma is a cancer of the immune system. Infection is a major cause of morbidity and mortality in patients with multiple myeloma. Some of these infections are preventable by vaccines available to the general population. However, little is known about the clinical effectiveness of these vaccines in patients with multiple myeloma, and the cellular and humoral immune response to vaccination has not been well characterized, especially in conjunction with modern myeloma therapies. The present report reviews the basics of multiple myeloma and the immune system, the available evidence on the immunologic response of patients with multiple myeloma after vaccination, and current practice recommendations regarding specific vaccines.
Categories: Hem/Oncs, Latest HeadlinesTweet-
Vaccination in Multiple Myeloma: Review of Current Literature [Jun 8, 2016] Alemu et al. @mtmdphd CLML https://t.co/bhwKr0nDDw #mmsm #ImmunoOnc #IDonc
-
-
Mashup Score: 1Multiple Myeloma Baseline Immunoglobulin G Level and Pneumococcal Vaccination Antibody Response - 8 month(s) ago
Infections are a major cause of morbidity and mortality in multiple myeloma (MM), a cancer of the immune system. Vaccination clinical efficacy endpoints have not been demonstrated, and there are limited data on surrogate markers of efficacy. This pilot study evaluated sequential immunologic markers after standard pneumococcal vaccination (PV) in patients with MM and non-MM controls. Vaccination was standard for PV (PCV13 or PPV23), with laboratory testing at baseline and at 2, 4, 12 and 24 weeks after vaccination. Immunoglobulin G (IgG) antibodies to pneumococcal antigens were detected by ELISA. Prevaccination total IgG levels and IgG subclass levels were also measured by ELISA. Four of 6 controls responded with at least a 2-fold increase in antibody concentration; only 2 controls had a sustained increase in concentration. Six of 8 patients with MM had at least a 2-fold antibody increase; however, only 2 of these patients showed a sustained increase of antipneumococcal antibody. Respon
Source: institutionalrepository.aah.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
Multiple Myeloma IgG Level & Pneumococcal Vaccination Ab Response [Aug 10, 2017] @mtmdphd et al. @JPCRR https://t.co/x5dZNhopn5 #mmsm #ImmunoOnc #IDonc https://t.co/FbGhCurz8b
-
-
Mashup Score: 1Investigation into aberrant B cell repertoire in myeloma on humoral immunity and patient survival. - 8 month(s) ago
8016 Background: B cells are critical to inhibiting tumor progression, as they generate tumor-reactive antibodies; promote anti-tumor killing capacity of NK cells and phagocytosis of macrophages/DCs; and enrich priming of T cells against the tumor. Multiple myeloma (MM) is a B-cell-derived malignancy, and its survival is partly driven by a deficiency in the immune response. Yet, the abnormalities of the B-cell-mediated humoral responses in MM are ill defined. Methods: We investigated B cell composition in bone marrow (BM) from patients with newly diagnosed MM (NDMM, N = 170), relapsed refractory MM (RRMM, N = 140) and healthy donors (HD, N = 21) by multi-color flow cytometry. Results: We observed that B1b cells was significantly reduced by 45% (p = 0.004) in NDMM patients compared to HD. B1b cells are important in generating long-lasting protective antibodies, particularly against vaccines, in a T cell independent fashion. Similarly, B2 cells, which can produce all antibody types, were
Source: ascopubs.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
Investigation into aberrant B cell repertoire in myeloma on humoral immunity and patient survival [May 31, 2023] @LBP0818 et al. #ASCO23 Abstract 8016 https://t.co/ncOFXseFoV #mmsm #IDonc #ImmunoOnc cc @DrTJM_MD @BilalAbidMD @DrJPHenderson
-
Did you know we have a VJHemOnc sessions page where you can explore exclusive roundtable discussions with leading experts in all areas of #hemonc? Check it out here: 👉 https://t.co/M0NfigPUP7 👈 #AMLsm #LeuSM #LymSM #MMsm #MPNsm #ImmunoOnc #MDSsm https://t.co/1bpkezhYJt